Drug
Gr181413a At1001
Gr181413a At1001: highest development phase Phase 1, developed by Amicus Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Amicus Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| GR181413A/AT1001 solution NCT01853852 | Phase 1 | Fabry Disease |
Latest
No recent events.
Follow Gr181413a At1001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.